home / stock / cyccp / cyccp news

CYCCP News and Press, Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock From 02/26/20

Stock Information
Company Name: Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock
Stock Symbol: CYCCP
Market: NASDAQ
Website: cyclacel.com
Menu
CYCCP CYCCP Quote CYCCP Short CYCCP News CYCCP Articles CYCCP Message Board
Get CYCCP Alerts

News, Short Squeeze, Breakout and More Instantly...
CYCCP - Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2019 Results - Earnings Call Transcript

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2019 Results Conference Call February 26, 2020 04:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Of...
CYCCP - Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor  and Fadraciclib -venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL – – Conference Call Scheduled February 26, 2...

CYCCP - Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results

BERKELEY HEIGHTS, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2019 fina...

CYCCP - Cyclacel Pharmaceuticals (CYCC) Presents At BIO CEO & Investor Conference 2020 - Slideshow

The following slide deck was published by Cyclacel Pharmaceuticals, Inc. in conjunction with this Read more ...

CYCCP - Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the B...

CYCCP - Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020

– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors  and CYC065-venetoclax combination in AML /MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (...

CYCCP - Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2020 in San Francisco

BERKELEY HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biote...
CYCCP - Cyclacel's CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias

BERKELEY HEIGHTS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, today announced study design and preliminary data from t...

CYCCP - Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results

– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, ...

CYCCP - Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results on Wedn...
Previous 10 Next 10